Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
The use of real-world evidence (RWE) in regulatory decision-making and health technology assessments (HTA) is gaining traction, particularly in the evolving landscape of oncology pharmacotherapeutics in Europe where navigating the drug approval and market access processes is becoming more complex.
In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation
Cancer clinical trials have long been the cornerstone of advancements in oncology, guiding the development of new therapies and improving patient outcomes.
Artificial intelligence (AI) has the potential to revolutionize drug development by leveraging real-world data (RWD) from electronic health records, claims data, patient registries, and wearable devices.
Valproate is the most effective treatment for idiopathic generalized epilepsy.
Discover an insightful webinar that focuses on the transformative potential of real-world data (RWD) in clinical research and healthcare strategy.
Pharmacoepidemiology, the study of the use and effects of drugs in large populations, has seen a significant evolution with the increasing availability of real-world data (RWD)
Join us for an insightful webinar, during which TriNetX experts explore how Europe’s evolving healthcare landscape is redefining the role of real-world evidence (RWE).
The global use of angiotensin receptor neprilysin inhibitor (ARNI) in clinical practice, especially in patients with heart failure and below-normal ejection fraction (HFbnEF), has not been thoroughly evaluated.
his study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.
Clinical research networks facilitate collaborative research, but data sharing remains a common barrier.
Upcoming Webinar
From Protocol Draft to Confident Feasibility: Democratizing Study Design with AI
Tuesday, September 15 | 10am ET
Join TriNetX and Parexel to explore how AI and real-world data are transforming clinical feasibility workflows.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
Not sure where to start?
Find the right solution for your organization
Take the Real-World Impact Assessment. Answer a few questions to see how TriNetX can drive impact across your clinical and commercial goals.
